Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: Clinical implications of the LUX-Lung 7 study

Keunchil Park

doi:10.21037/atm.2016.11.42

Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: Clinical implications of the LUX-Lung 7 study

Keunchil Park

Department of Internal Medicine

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Article number	476
Journal	Annals of Translational Medicine
Volume	4
Issue number	23
DOIs	https://doi.org/10.21037/atm.2016.11.42
State	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.21037/atm.2016.11.42

Cite this

@article{b5d58cdbd5a441ef8779285978cb8c33,

title = "Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: Clinical implications of the LUX-Lung 7 study",

author = "Keunchil Park",

year = "2016",

doi = "10.21037/atm.2016.11.42",

language = "English",

volume = "4",

journal = "Annals of Translational Medicine",

issn = "2305-5839",

publisher = "AME Publishing Company",

number = "23",

}

TY - JOUR

T1 - Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

T2 - Clinical implications of the LUX-Lung 7 study

AU - Park, Keunchil

PY - 2016

Y1 - 2016

UR - https://www.scopus.com/pages/publications/85006427811

U2 - 10.21037/atm.2016.11.42

DO - 10.21037/atm.2016.11.42

M3 - Letter

AN - SCOPUS:85006427811

SN - 2305-5839

VL - 4

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

IS - 23

M1 - 476

ER -

Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: Clinical implications of the LUX-Lung 7 study

UN SDGs

Access to Document

Other files and links

Cite this